Cancer remains as one of the most significant health problems, with approximately 19
million people diagnosed worldwide each year. Chemotherapy is a routinely used method to …

Poor targeting of therapeutics leading to severe adverse effects on normal tissues is
considered one of the obstacles in cancer therapy. To help overcome this, nanoscale drug …

Metal complexes are extensively used for cancer therapy. The multiple variables available
for tuning (metal, ligand, and metal–ligand interaction) offer unique opportunities for drug …

The development of PtIV prodrugs which are selectively reduced within cancerous cells into
their PtII therapeutically active species has received increasing attention within the last …

Prodrugs are chemically modified drug molecules that are inactive before administration.
After administration, they are converted in situ to parent drugs and induce the mechanism of …

Conventional light-driven cancer therapeutics require oxygen and visible light to indirectly
damage biomolecules, limiting their efficacy in deep, hypoxic tumours. Here we report the …

Encouraged by the worldwide success of cisplatin in the field of cancer chemotherapy,
intensive works have been conducted to explore more platinum coordination complexes as …

Activation of the cyclic GMP‐AMP synthase‐stimulator of the interferon gene (cGAS‐STING)
pathway is a potent anticancer immunotherapeutic strategy, and the induction of pyroptosis …

Selective activation of Pt (IV) prodrugs within tumors is particularly attractive because of their
low damage to normal tissues. However, current common activation via chemical …

The development of PtIV prodrugs that are reduced into the therapeutically active PtII
species within the tumor microenvironment has received much research interest. In order to …